

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/530,774
Filing Date	April 7, 2005
First Named Inventor	Bernard Roizman
Art Unit	1648
Examiner Name	Not Yet Assigned
Attorney Docket Number	27373/38819A

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Debinski, et al., "Receptor for Interleukin 13 is a Marker and Therapeutic Target for Human High-Grade Gliomas <sup>1</sup> ," Clin. Cancer Res. 5:985-990 (1999)	
		Debinski, et al., "Retargeting Interleukin 13 for Radioimmunodetection and Radioimmunotherapy of Human High-grade Gliomas," Clin. Cancer Res. 5(10 Suppl):3143s-3147s (1999)	
		Debinski, et al., "Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen," Mol. Med. 6:440-449 (2000)	
		de Vries et al., "Scintigraphic Imaging of HSVtk Gene Therapy," Current Pharmaceutical Design 8:1435-1450 (2002)	
		de Vries, et al., "Positron emission tomography: measurement of transgene expression," Methods 27(3):234-241 (2002)	
		Ellerman, et al., "Identification of a Determinant of Epidermal Growth Factor Receptor Ligand-Binding Specificity Using a Truncated, High-Affinity Form of the Ectodomain," Biochemistry 40:8930-8939 (2001)	
		Fracasso, et al., "Anti-tumor Effects of Toxins Targeted to the Prostate Specific Membrane Antigen," Prostate 53:9-23 (2002)	
		Gembitsky, et al., "A specific binding site for a fragment of the B-loop of epidermal growth factor and related peptides," Peptides 23:97-102 A. (2001)	
		Hayashi, et al., "MUC1 Mucin Core Protein Binds to the Domain 1 of ICAM-1," Digestion 63:87-92 (2001)	
		He, et al., "Suppression of the Phenotype of $\gamma_1$ 34.5 Herpes Simplex Virus 1: Failure of Activated RNA-Dependent Protein Kinase to Shut Off Protein Synthesis is Associated with a Deletion in the Domain of the $\alpha 47$ Gene," J. Virol. 71(8):6049-54 (1997)	
		International Search Report from PCT/US03/31598 (2004)	
		Laquerre, et al., "Heparan Sulfate Proteoglycan Binding by Herpes Simplex virus Type 1 Glycoproteins B and C, Which Differ in Their Contributions to Virus Attachment, Penetration, and Cell-to-Cell Spread," J. Virol. 72(7):6119-30 (1998)	
		Leib, et al., "Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses In Vivo," J. Exp. Med. 189:663-672 (1999)	
		Lorimer, et al., "Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe," J Immunol Methods 237(1-2):147-57 (2000)	
		Mabjeesh, et al., "Gene therapy of prostate cancer: current and future directions," Endo. Related Cancer 9:115-139 (2002)	
		Manoj et al., "Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism," Proc. Natl. Acad. Sci. USA., 101: 12414-12421 (2004)	
		Markert, et al., "Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial," Gene Ther. 7(10):867-74 (2000)	
		McKie, et al., "Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevant for gene and cancer therapy," Neuropathol Appl Neurobiol. 24(5):367-72 (1998)	
		Mineta, et al., "Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas," Nat Med., 1(9):938-43 (1995)	
		Mintz A., et al., "IL-13R $\alpha$ 2 is a Glioma-Restricted Receptor for Interleukin-13," Neoplasia 4:388-399 (2002)	
		Montgomery, et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family," Cell 87:427-436 (1996)	
		Pyles, et al., "A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain Tumors," Human Gene Ther. 8(5):533-44 (1997)	
		Ramplung, et al., "Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma," Gene Ther. 7(10):859-66 (2000)	

Examiner Signature	/Mary Mosher/	Date Considered	02/21/2008
--------------------	---------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/